New AI Software for Brain Bleed Diagnosis Receives FDA Clearance
|
By HospiMedica International staff writers Posted on 20 Nov 2018 |
|
Image: Product representations of the Accipio ICH detection software.
The US Food and Drug Administration (FDA) has given 510(k) clearance to the Accipio Ix intracranial hemorrhage (ICH) detection software developed by MaxQ AI (Tel Aviv, Israel), a clinical diagnostics intelligence platform company.
This will provide healthcare providers and physicians in acute care settings with access to the artificial intelligence (AI) software which has been designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of ICH, commonly known as a brain bleed.
MaxQ AI develops clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis as well as allow physicians to provide 'smarter care' with AI clinical insights. The company’s Accipio Ix ICH detection software leverages AI technology to automatically analyze non-contrast head CT images without workflow impact to the reader, altering the original series or storing Protected Health Information (PHI). Accipio Ix, part of MaxQ's Accipio INSIGHT platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with ICH for the treating physician. The AI-powered software provides the capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and cloud-capable.
"MaxQ's Accipio application, of which Accipio Ix is the first part of the ecosystem, provides physicians with actionable intelligence, improving their future ability to make a timely, accurate and more confident diagnosis of a brain bleed," said Gene Saragnese, Chairman and CEO of MaxQ AI. "Accipio Ix's ability to greatly increase suspected bleed detection, improve escalation and time to review is a game-changer. Further, our partnerships with top CT and PACS companies, including GE Healthcare, Samsung Neurologica and other organizations prior announced, make deployment and adoption of Accipio straightforward."
Related Links:
MaxQ AI
This will provide healthcare providers and physicians in acute care settings with access to the artificial intelligence (AI) software which has been designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of ICH, commonly known as a brain bleed.
MaxQ AI develops clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis as well as allow physicians to provide 'smarter care' with AI clinical insights. The company’s Accipio Ix ICH detection software leverages AI technology to automatically analyze non-contrast head CT images without workflow impact to the reader, altering the original series or storing Protected Health Information (PHI). Accipio Ix, part of MaxQ's Accipio INSIGHT platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with ICH for the treating physician. The AI-powered software provides the capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and cloud-capable.
"MaxQ's Accipio application, of which Accipio Ix is the first part of the ecosystem, provides physicians with actionable intelligence, improving their future ability to make a timely, accurate and more confident diagnosis of a brain bleed," said Gene Saragnese, Chairman and CEO of MaxQ AI. "Accipio Ix's ability to greatly increase suspected bleed detection, improve escalation and time to review is a game-changer. Further, our partnerships with top CT and PACS companies, including GE Healthcare, Samsung Neurologica and other organizations prior announced, make deployment and adoption of Accipio straightforward."
Related Links:
MaxQ AI
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Wound Irrigation Solution
Prontosan®
New
Patient Monitoring System
AlarmSense
Latest AI News
- Machine Learning Approach Enhances Liver Cancer Risk Stratification
- New AI Approach Monitors Brain Health Using Passive Wearable Data
- AI Tool Maps Early Risk Patterns in Bloodstream Infections
- AI Model Identifies Rare Endocrine Disorder from Hand Images
- AI Tool Promises to Reduce Length of Hospital Stays and Free Up Beds
- Machine Learning Model Cuts Canceled Liver Transplants By 60%
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Critical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
